Science Matters: Insights Into Gut-Brain Signaling Raise Hopes For Treating Neurological Disorders

New research offers mechanistic proof of signaling between gut and brain in Parkinson’s disease, showing that introducing an altered microbiome from PD patients into a mouse model can recreate the motor symptoms of the disease.

Scientist conducting a laboratory experiment in a cancer research facility in the United States, 1951.

Disruptive innovations sometimes come directly from the development of a novel enabling technology. In other cases, however, they result from focusing on a known problem using a different lens. Such creativity underlies new research suggesting the potential for harnessing the microbiome to treat neurological disorders.

A Dec. 1 paper in Cell offers mechanistic proof of signaling between gut and brain in Parkinson’s Disease (PD). It...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapy Areas

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By 

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.